Literature DB >> 26824949

A Complex Network of Interactions between S282 and G283 of Hepatitis C Virus Nonstructural Protein 5B and the Template Strand Affects Susceptibility to Sofosbuvir and Ribavirin.

Anupriya S Kulkarni1, Masad J Damha2, Raymond F Schinazi3, Hongmei Mo4, Brian Doehle4, Selena M Sagan1, Matthias Götte5.   

Abstract

The hepatitis C virus (HCV) RNA-dependent RNA-polymerase NS5B is essentially required for viral replication and serves as a prominent drug target. Sofosbuvir is a prodrug of a nucleotide analog that interacts selectively with NS5B and has been approved for HCV treatment in combination with ribavirin. Although the emergence of resistance to sofosbuvir is rarely seen in the clinic, the S282T mutation was shown to decrease susceptibility to this drug. S282T was also shown to confer hypersusceptibility to ribavirin, which is of potential clinical benefit. Here we devised a biochemical approach to elucidate the underlying mechanisms. Recent crystallographic data revealed a hydrogen bond between S282 and the 2'-hydroxyl of the bound nucleotide, while the adjacent G283 forms a hydrogen bond with the 2'-hydroxyl of the residue of the template that base pairs with the nucleotide substrate. We show that DNA-like modifications of the template that disrupt hydrogen bonding with G283 cause enzyme pausing with natural nucleotides. However, the specifically introduced DNA residue of the template reestablishes binding and incorporation of sofosbuvir in the context of S282T. Moreover, the DNA-like modifications of the template prevent the incorporation of ribavirin in the context of the wild-type enzyme, whereas the S282T mutant enables the binding and incorporation of ribavirin under the same conditions. Together, these findings provide strong evidence to show that susceptibility to sofosbuvir and ribavirin depends crucially on a network of interdependent hydrogen bonds that involve the adjacent residues S282 and G283 and their interactions with the incoming nucleotide and complementary template residue, respectively.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26824949      PMCID: PMC4808174          DOI: 10.1128/AAC.02436-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  32 in total

1.  Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

Authors:  John G McHutchison; Eric J Lawitz; Mitchell L Shiffman; Andrew J Muir; Greg W Galler; Jonathan McCone; Lisa M Nyberg; William M Lee; Reem H Ghalib; Eugene R Schiff; Joseph S Galati; Bruce R Bacon; Mitchell N Davis; Pabak Mukhopadhyay; Kenneth Koury; Stephanie Noviello; Lisa D Pedicone; Clifford A Brass; Janice K Albrecht; Mark S Sulkowski
Journal:  N Engl J Med       Date:  2009-07-22       Impact factor: 91.245

Review 2.  Treatment failure with new hepatitis C drugs.

Authors:  Vincent Soriano; Eugenia Vispo; Eva Poveda; Pablo Labarga; Pablo Barreiro
Journal:  Expert Opin Pharmacother       Date:  2012-01-14       Impact factor: 3.889

Review 3.  Sofosbuvir and ABT-450: terminator of hepatitis C virus?

Authors:  Qing-Lei Zeng; Ji-Yuan Zhang; Zheng Zhang; Li-Feng Wang; Fu-Sheng Wang
Journal:  World J Gastroenterol       Date:  2013-06-07       Impact factor: 5.742

Review 4.  Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection.

Authors:  Ira M Jacobson; Gary L Davis; Hashem El-Serag; Francesco Negro; Christian Trépo
Journal:  Clin Gastroenterol Hepatol       Date:  2010-08-14       Impact factor: 11.382

5.  Sofosbuvir for previously untreated chronic hepatitis C infection.

Authors:  Eric Lawitz; Alessandra Mangia; David Wyles; Maribel Rodriguez-Torres; Tarek Hassanein; Stuart C Gordon; Michael Schultz; Mitchell N Davis; Zeid Kayali; K Rajender Reddy; Ira M Jacobson; Kris V Kowdley; Lisa Nyberg; G Mani Subramanian; Robert H Hyland; Sarah Arterburn; Deyuan Jiang; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Aasim M Sheikh; Zobair Younossi; Edward J Gane
Journal:  N Engl J Med       Date:  2013-04-23       Impact factor: 91.245

6.  Structure of hepatitis C virus polymerase in complex with primer-template RNA.

Authors:  Ralph T Mosley; Thomas E Edwards; Eisuke Murakami; Angela M Lam; Rena L Grice; Jinfa Du; Michael J Sofia; Philip A Furman; Michael J Otto
Journal:  J Virol       Date:  2012-04-11       Impact factor: 5.103

7.  Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977.

Authors:  Eisuke Murakami; Tatiana Tolstykh; Haiying Bao; Congrong Niu; Holly M Micolochick Steuer; Donghui Bao; Wonsuk Chang; Christine Espiritu; Shalini Bansal; Angela M Lam; Michael J Otto; Michael J Sofia; Phillip A Furman
Journal:  J Biol Chem       Date:  2010-08-26       Impact factor: 5.157

8.  De novo initiation of RNA synthesis by the RNA-dependent RNA polymerase (NS5B) of hepatitis C virus.

Authors:  G Luo; R K Hamatake; D M Mathis; J Racela; K L Rigat; J Lemm; R J Colonno
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

9.  Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance.

Authors:  Megan H Powdrill; Egor P Tchesnokov; Robert A Kozak; Rodney S Russell; Ross Martin; Evguenia S Svarovskaia; Hongmei Mo; Roger D Kouyos; Matthias Götte
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-01       Impact factor: 11.205

10.  Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.

Authors:  Michael J Sofia; Donghui Bao; Wonsuk Chang; Jinfa Du; Dhanapalan Nagarathnam; Suguna Rachakonda; P Ganapati Reddy; Bruce S Ross; Peiyuan Wang; Hai-Ren Zhang; Shalini Bansal; Christine Espiritu; Meg Keilman; Angela M Lam; Holly M Micolochick Steuer; Congrong Niu; Michael J Otto; Phillip A Furman
Journal:  J Med Chem       Date:  2010-10-14       Impact factor: 7.446

View more
  3 in total

1.  Mutations Identified in the Hepatitis C Virus (HCV) Polymerase of Patients with Chronic HCV Treated with Ribavirin Cause Resistance and Affect Viral Replication Fidelity.

Authors:  Niels Mejer; Ulrik Fahnøe; Andrea Galli; Santseharay Ramirez; Ola Weiland; Thomas Benfield; Jens Bukh
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191

Review 2.  Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond.

Authors:  Ashley N Matthew; Florian Leidner; Gordon J Lockbaum; Mina Henes; Jacqueto Zephyr; Shurong Hou; Desaboini Nageswara Rao; Jennifer Timm; Linah N Rusere; Debra A Ragland; Janet L Paulsen; Kristina Prachanronarong; Djade I Soumana; Ellen A Nalivaika; Nese Kurt Yilmaz; Akbar Ali; Celia A Schiffer
Journal:  Chem Rev       Date:  2021-01-07       Impact factor: 60.622

3.  Molecular Characterization of Hepatitis C Virus for Developed Antiviral Agents Resistance Mutations and New Insights into in-silico Prediction Studies.

Authors:  Mohamed M Adel El-Sokkary; Lizaveta Gotina; Mohammad M Al-Sanea; Ae Nim Pae; Rehab Mohammed Elbargisy
Journal:  Infect Drug Resist       Date:  2020-11-23       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.